Navigation Links
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
Date:3/4/2013

treatments for multiple types of patients," said Peter Piliero , MD, vice president, Clinical and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "These new data add to our expanding body of clinical evidence on faldaprevir as we continue to pursue HCV treatment options for a diverse range of patients that physicians frequently encounter in clinical practice."

About STARTVerso™ 4

STARTVerso™ 4 is an open-label, sponsor blinded, Phase 3 study assessing the efficacy and safety of Boehringer Ingelheim's investigational oral protease inhibitor faldaprevir in combination with PegIFN/RBV. The study includes 308 individuals co-infected with HCV and HIV who were treatment-naive (TN) or had relapsed after previous HCV therapy with PegIFN/RBV, and were either HIV treatment-naive or being treated with ART. The trial includes patients with cirrhosis (17% had F4 cirrhosis or Fibroscan >13 kPa).

  • Group 1: 12 or 24 weeks of faldaprevir 240mg once-daily in addition to 24 or 48 weeks of PegIFN/RBV
  • Group 2: 24 weeks of faldaprevir 120mg once-daily in addition to 24 or 48 weeks of PegIFN/RBV

About Boehringer Ingelheim in Hepatitis C Virus (HCV)

In partnership with the scientific community, our clinical trial program, HCVerso™, is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. The ongoing multi-study Phase 3 STARTVerso™ trial program, evaluating faldaprevir combined with PegIFN/RBV in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV, is near clinical completion. BI 207127 is an investigational NS5B non-nucleoside polymerase in
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... Company announces the recent formation of Alamo ... wholly owned subsidiary of Mission, will provide ... resources (HR) support.  Alamo will be headquartered ... States presence, which also includes the company,s ...
... Jan. 26, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc.- Florida has reached a settlement with ... Watson,s generic versions of Mallinckrodt,s Exalgo® (Hydromorphone Hydrochloride ... December 10, 2010 in the United States District ...
Cached Medicine Technology:Mission Pharmacal Launches Alamo Pharma Services 2Mission Pharmacal Launches Alamo Pharma Services 3Watson Reaches Settlement with Mallinckrodt Over Exalgo(R) 2
(Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... EDITOR,S PICK: Reducing the health risks of obesity without serious ... as a treatment for obesity and its myriad of serious ... desired effects on weight, which it decreased, and on levels ... approved for use in the US because of serious neurological ...
... million African women and children could be saved by ... The Partnership for Maternal, Newborn & Child Health and ... Countdown report estimates that these interventions -- antenatal care, ... treatment of childhood illnesses, and immunization, among others -- ...
... physicians are often poor judges of their patients, health ... Street from Texas A&M University and Paul Haidet from ... However, physicians, understanding is better the more patients are ... beliefs and preferences for care. Their analysis 1 ...
... seeks to improve patient care by further limiting the ... Research will published a new study online on Monday ... and laparoscopic cholecystectomy were similar among residents who ... had worked more than 16 hours. The research ...
... years ago today, the world,s first baby was born ... to the birth of Louise Brown on 25 July ... Medical Research Council decided in 1971 against providing the ... Steptoe with long-term financial support. Today, an intriguing paper ...
... disease developed at the Los Angeles Biomedical Research Institute ... I. Meyer, PhD, LA BioMed president and CEO announced ... the sickle cell treatment developed by investigators led by ... to Emmaus Medical, Inc. The patented drug treatment involves ...
Cached Medicine News:Health News:JCI table of contents: July 26, 2010 2Health News:JCI table of contents: July 26, 2010 3Health News:JCI table of contents: July 26, 2010 4Health News:JCI table of contents: July 26, 2010 5Health News:JCI table of contents: July 26, 2010 6Health News:JCI table of contents: July 26, 2010 7Health News:Small investment could save 11 million African lives 2Health News:Small investment could save 11 million African lives 3Health News:Small investment could save 11 million African lives 4Health News:Small investment could save 11 million African lives 5Health News:Small investment could save 11 million African lives 6Health News:Small investment could save 11 million African lives 7Health News:Small investment could save 11 million African lives 8Health News:Small investment could save 11 million African lives 9Health News:Doctors don't 'get' their patients 2Health News:Rest requirements for residents unlikely to improve outcomes in 2 common surgeries 2Health News:Rest requirements for residents unlikely to improve outcomes in 2 common surgeries 3Health News:Why the MRC didn't fund research that led to the birth of the world's first test tube baby 2Health News:Why the MRC didn't fund research that led to the birth of the world's first test tube baby 3Health News:Why the MRC didn't fund research that led to the birth of the world's first test tube baby 4Health News:Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: